UNSPSC 51371700: Controlled substance analgesic indole alkaloids

Controlled substance analgesic drugs made from group of alkaloids containing a benzylpyrrole group (derived from tryptophan)

UNSPSC 51371700 Controlled substance analgesic indole alkaloids is a Class code under which state and local governments procure pharmaceutical products and related delivery systems, including naloxone and safe drug deactivation systems for community health and emergency response use, as well as generic multi-source pharmaceuticals and over-the-counter products supplied through authorized wholesale channels. Solicitations under this code reflect direct procurement of naloxone units and drug management systems for public health initiatives, along with broader pharmaceutical supply agreements managed through cooperative purchasing alliances. Issuing bodies include county health departments (Seminole County, Florida), state health and human services agencies (Texas Health and Human Services Commission), and multistate cooperative purchasing organizations (Minnesota Multistate Cooperative Purchasing Alliance administering on behalf of participating state and local government facilities across multiple jurisdictions including Oregon).

Recent activity spans Florida, Texas, and Minnesota. Seminole County, Florida posted IFB 60459723LAS on June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries due by July 26, 2023; the procurement requires compliance with E-Verify, drug-free workplace certification, and carries a three-month probationary termination clause. The Texas Health and Human Services Commission issued RFI HHS0017013 in April 2026 to assess vendor capacity for direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager and wholesaler relationships, gathering market intelligence before formal RFP development. The Minnesota Multistate Cooperative Purchasing Alliance released RFP S1070000015802 on January 20, 2026, establishing multiple contracts for generic pharmaceuticals and OTC products through AmerisourceBergen, Cardinal Health, and Morris & Dickson, with proposals due March 26, 2026; awarded vendors must comply with cGMP and Drug Supply Chain Security Act certification, maintain $5 million general liability coverage, and accept a 3 percent administrative fee on all purchases.